Clinical Trial

JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure

Name: JDB153 Combined With Serplulimab for Pancreatic Cancer After Standard Treatment Failure — clinical trial record (NCT07175389)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Not Yet Recruiting Phase 1/2

View on ClinicalTrials.gov →

Summary

The goal of this clinical trial is to evaluate the safety and efficacy of JDB153 combined with Serplulimab in patients with pancreatic cancer after standard treatment failure.

Trial Details

NCT Number	NCT07175389
Lead Sponsor	West China Hospital
Conditions	Refractory Pancreatic Ductal Adenocarcinoma, Refractory Pancreatic Adenocarcinoma
Enrollment	10 participants
Start Date	2025-10-01
Primary Completion	2027-09-01 (estimated)
Study Completion	2027-10-01 (estimated)
Updated on ClinicalTrials.gov	2025-09-16